Efficacy and safety of on-demand versus daily rupatadine in chronic spontaneous urticaria: A randomized trial.
chronic spontaneous urticaria
disease activity
on-demand
rupatadine
updosing
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
19 Aug 2023
19 Aug 2023
Historique:
revised:
25
05
2023
received:
11
04
2023
accepted:
16
06
2023
medline:
19
8
2023
pubmed:
19
8
2023
entrez:
19
8
2023
Statut:
aheadofprint
Résumé
Non-sedating H This multicenter, randomized study consisted of 2 weeks of screening, 8 weeks of double-blind treatment, and 6 weeks of treatment-free follow-up (OD allowed). Adult patients were randomized to 10 mg rupatadine OD or 10 mg rupatadine daily. At Week 4, if patients did not have a complete response, they switched from 10 to 20 mg rupatadine daily or underwent sham updosing (patients on 10 mg rupatadine OD). The primary aim was to compare CSU disease activity at the end of follow-up between daily versus OD. Additionally, we assessed the efficacy of rupatadine updosing. Major outcomes were disease activity, CSU-related quality of life (QoL), and disease control. At Week 4, disease activity and QoL significantly improved in daily versus OD-treated patients. Updosing of rupatadine did not improve the mean disease activity, but the number of complete responders increased during updosing from 5% to 22%. At the end of follow-up, the disease activity of patients treated OD versus daily was not significantly different. Daily rupatadine treatment significantly improved CSU disease activity and QoL during treatment versus OD treatment but not after discontinuation of rupatadine, indicating the benefits of a daily maintenance nsAH schedule.
Sections du résumé
BACKGROUND
BACKGROUND
Non-sedating H
METHODS
METHODS
This multicenter, randomized study consisted of 2 weeks of screening, 8 weeks of double-blind treatment, and 6 weeks of treatment-free follow-up (OD allowed). Adult patients were randomized to 10 mg rupatadine OD or 10 mg rupatadine daily. At Week 4, if patients did not have a complete response, they switched from 10 to 20 mg rupatadine daily or underwent sham updosing (patients on 10 mg rupatadine OD). The primary aim was to compare CSU disease activity at the end of follow-up between daily versus OD. Additionally, we assessed the efficacy of rupatadine updosing. Major outcomes were disease activity, CSU-related quality of life (QoL), and disease control.
RESULTS
RESULTS
At Week 4, disease activity and QoL significantly improved in daily versus OD-treated patients. Updosing of rupatadine did not improve the mean disease activity, but the number of complete responders increased during updosing from 5% to 22%. At the end of follow-up, the disease activity of patients treated OD versus daily was not significantly different.
CONCLUSIONS
CONCLUSIONS
Daily rupatadine treatment significantly improved CSU disease activity and QoL during treatment versus OD treatment but not after discontinuation of rupatadine, indicating the benefits of a daily maintenance nsAH schedule.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Charité - Universitätsmedizin Berlin
Organisme : Uriach
Informations de copyright
© 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734-766. (In English). doi:10.1111/all.15090
Kolkhir P, Giménez-Arnau AM, Kulthanan K, Peter J, Metz M, Maurer M. Urticaria. Nat Rev Dis Primers. 2022;8(1):61. (In English). doi:10.1038/s41572-022-00389-z
Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy. 2011;66(3):317-330. (In English). doi:10.1111/j.1398-9995.2010.02496.x
Gonçalo M, Gimenéz-Arnau A, Al-Ahmad M, et al. The global burden of chronic urticaria for the patient and society. Br J Dermatol. 2021;184(2):226-236. (In English). doi:10.1111/bjd.19561
Radonjic-Hoesli S, Hofmeier KS, Micaletto S, Schmid-Grendelmeier P, Bircher A, Simon D. Urticaria and angioedema: an update on classification and pathogenesis. Clin Rev Allergy Immunol. 2018;54(1):88-101. (In English). doi:10.1007/s12016-017-8628-1
Canonica GW, Fumagalli F, Guerra L, et al. Levocetirizine in persistent allergic rhinitis: continuous or on-demand use? A pilot study. Curr Med Res Opin. 2008;24(10):2829-2839. (In English). doi:10.1185/03007990802395927
Ciprandi G, Passalacqua G, Mincarini M, Ricca V, Canonica GW. Continuous versus on demand treatment with cetirizine for allergic rhinitis. Ann Allergy Asthma Immunol. 1997;79(6):507-511. (In English). doi:10.1016/s1081-1206(10)63057-8
Ciprandi G, Tosca M, Passalacqua G, Canonica GW. Long-term cetirizine treatment reduces allergic symptoms and drug prescriptions in children with mite allergy. Ann Allergy Asthma Immunol. 2001;87(3):222-226. (In English). doi:10.1016/s1081-1206(10)62230-2
Grob JJ, Auquier P, Dreyfus I, Ortonne JP. How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life. Allergy. 2009;64(4):605-612. (In English). doi:10.1111/j.1398-9995.2008.01913.x
Siebenhaar F, Degener F, Zuberbier T, Martus P, Maurer M. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol. 2009;123(3):672-679. (In English). doi:10.1016/j.jaci.2008.12.008
Staevska M, Popov TA, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010;125(3):676-682. (In English). doi:10.1016/j.jaci.2009.11.047
Weller K, Viehmann K, Bräutigam M, et al. Management of chronic spontaneous urticaria in real life-in accordance with the guidelines? A cross-sectional physician-based survey study. J Eur Acad Dermatol Venereol. 2013;27(1):43-50. (In English). doi:10.1111/j.1468-3083.2011.04370.x
Weller K, Ziege C, Staubach P, et al. H1-antihistamine up-dosing in chronic spontaneous urticaria: patients' perspective of effectiveness and side effects-a retrospective survey study. PLoS ONE. 2011;6(9):e23931. (In English). doi:10.1371/journal.pone.0023931
Türk M, Yılmaz İ, Şahiner ÜM, et al. Experience-based advice on stepping up and stepping down the therapeutic management of chronic spontaneous urticaria: where is the guidance? Allergy. 2022;77(5):1626-1630. (In English). doi:10.1111/all.15227
Takeshi Kono MK. Evaluation of the prognosis of chronic urticaria with antihistamine therapy (EPOCH). EADV. 2010.
AP Ltd. Rupatadine 1 mg/ml Oral Solution. EMC; 2022.
AP Ltd. Rupatadine 10 mg Tablets. EMC; 2022.
Pałgan K, Bartuzi Z. Platelet activating factor in allergies. Int J Immunopathol Pharmacol. 2015;28(4):584-589. (In English). doi:10.1177/0394632015600598
Munoz-Cano R, Ainsua-Enrich E, Torres-Atencio I, et al. Effects of rupatadine on platelet-activating factor-induced human mast cell degranulation compared with desloratadine and levocetirizine (the MASPAF study). J Investig Allergol Clin Immunol. 2017;27(3):161-168. (In English). doi:10.18176/jiaci.0117
Mullol J, Bousquet J, Bachert C, et al. Update on rupatadine in the management of allergic disorders. Allergy. 2015;70(Suppl 100):1-24. (In English). doi:10.1111/all.12531
Krause K, Giménez-Arnau A, Martinez-Escala E, et al. Platelet-activating factor (PAF) induces wheal and flare skin reactions independent of mast cell degranulation. Allergy. 2013;68(2):256-258. (In English). doi:10.1111/all.12083
Vasiadi M, Kalogeromitros D, Kempuraj D, et al. Rupatadine inhibits proinflammatory mediator secretion from human mast cells triggered by different stimuli. Int Arch Allergy Immunol. 2010;151(1):38-45. (In English). doi:10.1159/000232569
Peña J, Carbo ML, Solans A, Nadal T, Izquierdo I, Merlos M. Antihistaminic effects of rupatadine and PKPD modelling. Eur J Drug Metab Pharmacokinet. 2008;33(2):107-116. (In English). doi:10.1007/bf03191027
Valero A, de la Torre F, Castillo JA, et al. Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis: a multicentre, open-label study in Spain. Drug Saf. 2009;32(1):33-42. (In English). doi:10.2165/00002018-200932010-00003
Metz M, Scholz E, Ferrán M, Izquierdo I, Giménez-Arnau A, Maurer M. Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. Ann Allergy Asthma Immunol. 2010;104(1):86-92. (In English). doi:10.1016/j.anai.2009.11.013
Giménez-Arnau A, Izquierdo I, Maurer M. The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo-controlled treatment with rupatadine 10 and 20 mg. J Eur Acad Dermatol Venereol. 2009;23(9):1088-1091. (In English). doi:10.1111/j.1468-3083.2009.03289.x
Hawro T, Ohanyan T, Schoepke N, et al. The urticaria activity score-validity, reliability, and responsiveness. J Allergy Clin Immunol Pract. 2018;6(4):1185-1190.e1. (In English). doi:10.1016/j.jaip.2017.10.001
Weller K, Groffik A, Church MK, et al. Development and validation of the urticaria control test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol. 2014;133(5):1365-1372.e6. (In English). doi:10.1016/j.jaci.2013.12.1076
Finlay AY, Khan GK. Dermatology life quality index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-216. (In English). doi:10.1111/j.1365-2230.1994.tb01167.x
Baiardini I, Pasquali M, Braido F, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). Allergy. 2005;60(8):1073-1078. (In English). doi:10.1111/j.1398-9995.2005.00833.x
Salmun LM, Lorber R. 24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139]. BMC Fam Pract. 2002;3:14. (In English). doi:10.1186/1471-2296-3-14
Sussman GL, Mason J, Compton D, Stewart J, Ricard N. The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis. J Allergy Clin Immunol. 1999;104(1):100-106. (In English). doi:10.1016/s0091-6749(99)70120-x
Donado E, Izquierdo I, Pérez I, et al. No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a 'thorough QT/QTc study' performed according to ICH guidelines. Br J Clin Pharmacol. 2010;69(4):401-410. (In English). doi:10.1111/j.1365-2125.2009.03599.x
Dizdar EA, Sekerel BE, Keskin O, et al. The effect of regular versus on-demand desloratadine treatment in children with allergic rhinitis. Int J Pediatr Otorhinolaryngol. 2007;71(6):843-849. (In English). doi:10.1016/j.ijporl.2007.02.003
Thangam EB, Jemima EA, Singh H, et al. The role of histamine and histamine receptors in mast cell-mediated allergy and inflammation: the hunt for new therapeutic targets. Front Immunol. 2018;9:1873. (In English). doi:10.3389/fimmu.2018.01873